Mitoxantrone Completed Phase 2 Trials for Myelodysplastic Syndromes / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00015951Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
NCT00458848Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
NCT00002598Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
NCT00002674Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
NCT00002805Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00006122Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
NCT00053131Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT00070174Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
NCT00109837S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00274807Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00337246Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia